series-a
Stage
1
Investors
About
Ahammune is a clinical-stage biotech company developing small-molecule drugs targeting immune-mediated skin diseases, with a lead candidate focused on treating vitiligo.
Explore Ahammune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.